Compare JetBlue Airways Corporation (JBLU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Twist Bioscience Corp — how do they compare? JetBlue Airways Corporation trades at $3.91 (market cap $1.50B), while Twist Bioscience Corp trades at $157.11 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 6.9× JetBlue Airways Corporation's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Twist Bioscience Corp for 27 Days on average.
| JBLU | TWST | |
|---|---|---|
Market Cap | $1.50B | $10.32B |
Volume | 22,018,927 | 5,894,998 |
Sector | Industrials | Health |
52-Week High | $6.46 | $205.00 |
52-Week Low | $3.92 | $25.45 |
Typical Hold Time | 44 Days | 27 Days |
Enterprise Value | $8.86B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.97, down 1.49% on the day, with the stock showing bearish technical momentum despite trading near its 52-week low. The company continues to face fundamental challenges with negative net income margins (-9.32% in 2025) and declining revenue trends, though valuation metrics like P/S (0.15) and P/B (0.94) appear attractive. Recent developments include route expansion to Colombia and the launch of BlueFirst premium seating, while activist investor Carl Icahn recently exited board positions per the 2024 agreement.
The outlook remains challenging with persistent losses and high debt levels (debt-to-asset ratio over 50%), though analyst consensus targets $5.89 suggesting potential upside. Key risks include elevated fuel costs, competitive pressures, and ongoing negative cash flow from operations. Investment opportunity exists for value investors betting on operational turnaround, but requires careful risk management given the company's financial strain.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
